

GLAXOSMITHKLINE PLC
Form 6-K
October 13, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 13 October 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes ☐ No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|-------------------------------------|-------------------------|
| a) Name | Ms E Walmsley |
| b) Position / status | Chief Executive Officer |
| c) Initial notification / amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- | | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- | | | | | | |
|--|--|----------|-----------|----------|----|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | | | | |
| b) Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017, on shares held through the Company's Share Reward Plan. | | | | |
| c) Price(s) and volume(s) | <table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£15.2816</td> <td>14</td> </tr> </table> | Price(s) | Volume(s) | £15.2816 | 14 |
| Price(s) | Volume(s) | | | | |
| £15.2816 | 14 | | | | |
| Aggregated information | n/a (single transaction) | | | | |
| d) Aggregated volume
Price | | | | | |
| e) Date of the transaction | 2017-10-12 | | | | |
| f) Place of the transaction | London Stock Exchange (XLON) | | | | |

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
- b) Position / status President, Global Manufacturing & Supply
- c) Initial notification / amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £15.2816 | 57 |
- n/a (single transaction)
- Aggregated information
- d) Aggregated volume
Price
- e) Date of the transaction 2017-10-12
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S Dingemans
- b) Position / status Chief Financial Officer
- c) Initial notification / amendment Initial notification

Details of the issuer, emission allowance market participant, auction
2. platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary
Shares following the
re-investment of dividends
paid to shareholders on 12
October 2017, on shares held
through the Company's Share
Reward Plan.

c) Price(s) and volume(s) Price(s) Volume(s)
£15.2816 20

Aggregated information

d) Aggregated volume n/a (single transaction)
Price

e) Date of the transaction 2017-10-12

f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons
b) Position / status SVP, Global Ethics &
Compliance
c) Initial notification / amendment Initial notification

Details of the issuer, emission allowance market participant, auction
2. platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- | | | | | | |
|--|--|----------|-----------|----------|---|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | | | | |
| b) Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017, on shares held through the Company's Share Reward Plan. | | | | |
| c) Price(s) and volume(s) | <table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£15.2816</td> <td>7</td> </tr> </table> | Price(s) | Volume(s) | £15.2816 | 7 |
| Price(s) | Volume(s) | | | | |
| £15.2816 | 7 | | | | |
| Aggregated information | n/a (single transaction) | | | | |
| d) Aggregated volume Price | | | | | |
| e) Date of the transaction | 2017-10-12 | | | | |
| f) Place of the transaction | London Stock Exchange (XLON) | | | | |
1. Details of PDMR/person closely associated with them ('PCA')
- | | |
|-------------------------------------|------------------------|
| a) Name | Mr D S Redfern |
| b) Position / status | Chief Strategy Officer |
| c) Initial notification / amendment | Initial notification |
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- | | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- | | |
|--|--|
| a) Description of the financial instrument | |
|--|--|

Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary
Shares following the
re-investment of dividends
paid to shareholders on 12
October 2017, on shares held
through the Company's Share
Reward Plan.

c) Price(s) and volume(s) Price(s) Volume(s)
£15.2816 65

Aggregated information n/a (single transaction)

d) Aggregated volume
Price

e) Date of the transaction 2017-10-12

f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position / status SVP, Human Resources

c) Initial notification / amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary
Shares following the
re-investment of dividends

paid to shareholders on 12 October 2017, on shares held through the Company's Share Reward Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.2816	65

Aggregated information n/a (single transaction)

d) Aggregated volume
Price

e) Date of the transaction 2017-10-12

f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson

b) Position / status President, Global Affairs

c) Initial notification / amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017, on shares held through the Company's Share Reward Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.2816	35

Aggregated information	n/a (single transaction)	
d) Aggregated volume Price		
e) Date of the transaction	2017-10-12	
f) Place of the transaction	London Stock Exchange (XLON)	
1. Details of PDMR/person closely associated with them ('PCA')		
a) Name	Dr P J T Vallance	
b) Position / status	President, R&D	
c) Initial notification / amendment	Initial notification	
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a) Name	GlaxoSmithKline plc	
b) LEI	5493000HZTVUYLO1D793	
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017, on shares held through the Company's Share Reward Plan.	
c) Price(s) and volume(s)	Price(s) £15.2816	Volume(s) 39
Aggregated information	n/a (single transaction)	
d) Aggregated volume Price		
e) Date of the transaction	2017-10-12	

- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mrs V A Whyte
- b) Position / status Company Secretary
- c) Initial notification / amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £15.2816 | 46 |
- Aggregated information n/a (single transaction)
- d) Aggregated volume
Price
- e) Date of the transaction 2017-10-12
- f) Place of the transaction London Stock Exchange (XLON)

SIGNATURES

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: October 13, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc